Orexigen buys U.S. rights to obesity drug from Takeda
March 15 (Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co .
Orexigen said it had also entered into a deal with Canada's Valeant Pharmaceuticals International Inc to sell the treatment in central and eastern Europe. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)
© Thomson Reuters 2017 All rights reserved.